![Frontiers | Maternal and Fetal Outcomes After Interferon Exposure During Pregnancy: A Systematic Review With Meta-Analysis Frontiers | Maternal and Fetal Outcomes After Interferon Exposure During Pregnancy: A Systematic Review With Meta-Analysis](https://www.frontiersin.org/files/Articles/702929/frph-03-702929-HTML/image_m/frph-03-702929-g001.jpg)
Frontiers | Maternal and Fetal Outcomes After Interferon Exposure During Pregnancy: A Systematic Review With Meta-Analysis
![JCM | Free Full-Text | Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals JCM | Free Full-Text | Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals](https://www.mdpi.com/jcm/jcm-12-02195/article_deploy/html/images/jcm-12-02195-g001-550.jpg)
JCM | Free Full-Text | Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
![Short versus standard treatment with Pegylated interferon alfa-2a plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the CLEO trial. – topic of research paper in Clinical medicine. Download Short versus standard treatment with Pegylated interferon alfa-2a plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the CLEO trial. – topic of research paper in Clinical medicine. Download](https://cyberleninka.org/viewer_images/415062/f/1.png)
Short versus standard treatment with Pegylated interferon alfa-2a plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the CLEO trial. – topic of research paper in Clinical medicine. Download
![Pegylated interferon-α2b and ribavirin decrease claudin-1 and E-cadherin expression in HepG2 and Huh-7.5 cells | Annals of Hepatology Pegylated interferon-α2b and ribavirin decrease claudin-1 and E-cadherin expression in HepG2 and Huh-7.5 cells | Annals of Hepatology](https://multimedia.elsevier.es/PublicationsMultimediaV1/file//16652681/0000001200000004/v1_201906141018/S1665268119313468/v1_201906141018/en/main.assets/gr4.jpeg?xkr=ue/ImdikoIMrsJoerZ+w997EogCnBdOOD93cPFbanNeKOJqKH5+Za6P+RA5Vq9Dloi2SjpU87RVqB5pdExBba3/KeVEoWrN/INBR1hyeUSChREjkHslqd8Qt3WrBSUT9cHewJmG5dYRLLF6/XghJew1Go3rJ60kHMUf36eonWrVyOtaocB2VUVKo/QZJZjwgx80XVpbTqlx+72Aiwigq2GGR2PSFke0Gucl6a6uDIOIiQ2tbRT8jKwN303stHiOhTiS+z8TeomLIDbP9EFUNMuST5j/nPep9tBk/2zd0SdM=)
Pegylated interferon-α2b and ribavirin decrease claudin-1 and E-cadherin expression in HepG2 and Huh-7.5 cells | Annals of Hepatology
![Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients with Recurrent Hepatitis C Infection - American Journal of Transplantation Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients with Recurrent Hepatitis C Infection - American Journal of Transplantation](https://www.amjtransplant.org/cms/asset/40fab763-8265-49fa-b83c-10993a4261d6/gr1.jpg)
Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients with Recurrent Hepatitis C Infection - American Journal of Transplantation
Final Appraisal Determination - Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatit
Treatment of chronic hepatitis C in children with pegylated interferon and ribavirin : the impact of dose ORIGINAL ARTICLE
![Psychiatric side effects of pegylated interferon‑α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta‑analysis Psychiatric side effects of pegylated interferon‑α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta‑analysis](https://www.spandidos-publications.com/article_images/etm/16/2/etm-16-02-0971-g02.jpg)
Psychiatric side effects of pegylated interferon‑α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta‑analysis
The use of interferon alfa, peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
![PDF] Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. | Semantic Scholar PDF] Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9ced2b2becd29b4342952a49f534b2f9f0e08131/3-Figure1-1.png)
PDF] Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. | Semantic Scholar
![Cureus | Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection | Article Cureus | Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection | Article](https://assets.cureus.com/uploads/figure/file/236735/article_show_86a98550df4b11ebafa4d34d891be251-Screen-Shot-2021-07-02-at-12.12.59-AM.webp)
Cureus | Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection | Article
![Viruses | Free Full-Text | Unmet Needs for the Treatment of Chronic Hepatitis E Virus Infection in Immunocompromised Patients Viruses | Free Full-Text | Unmet Needs for the Treatment of Chronic Hepatitis E Virus Infection in Immunocompromised Patients](https://www.mdpi.com/viruses/viruses-14-02116/article_deploy/html/images/viruses-14-02116-g001.png)
Viruses | Free Full-Text | Unmet Needs for the Treatment of Chronic Hepatitis E Virus Infection in Immunocompromised Patients
![Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial - The Lancet Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/2119418385/2093586859/gr1.gif)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial - The Lancet
![Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B | SpringerLink Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12072-020-10098-y/MediaObjects/12072_2020_10098_Figa_HTML.png)
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B | SpringerLink
![PDF) Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan | Kow-tong Chen - Academia.edu PDF) Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan | Kow-tong Chen - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/80229518/mini_magick20220205-32277-1pzibsh.png?1644049410)
PDF) Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan | Kow-tong Chen - Academia.edu
![Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C | Nature Reviews Gastroenterology & Hepatology Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fnrgastro.2011.21/MediaObjects/41575_2011_Article_BFnrgastro201121_Fig5_HTML.jpg)